References
- Annual Report Belgian Cystic Fibrosis Registry (BCFR 2019), Brussels (Belgium).
- Cystic Fibrosis Foundation Patient Registry Annual Data Report, 2019, Bethesda.
- Goss C, Muhlebach M. Review: staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros. 2011;10(5):298–306.
- Vanderhelst E, De Meirleir L, et al. Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients. J Cystic Fibr. 2012 Jan;11(1):2–7.
- Gilpin D, Hoffman L, Ceppe A, et al. Phenotypic characteristics of incident and chronic MRSA isolates in cystic fibrosis. J Cyst Fibros. 2021;20(4):692–698. article in press.
- Akil N, Muhlebach M. Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis. Pediatr Pulmonol. 2018;53(S3):S64–S74.
- Russo K, Donnelly M, Reid AJM. Segregation-the perspectives of young patients and their parents. J Cystis Fibr. 2006;5(2):93–99.
- Kiefer A, Bogdan C, Melichar VO. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm Med. 2018;18(1):20.
- Kerem A, Conway S, Elborn S, et al. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005;4(1):7–26.
- Lo D, Muhlebach M, Smyth A. Interventions for the erdication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (Review). Cochrane Database Syst Rev. 2018;7(7):CD009650.
- Hall H, Gadhok R, Alshafi K, et al. Eradication of respiratory tract MRSA at a large adult CF centre. Respir Med. 2015;109(3):357–363.
- Doe SJ, McSorley A, Isalska B, et al. Patient segregation and aggressive antibiotic eradication therapy can control MRSA at large CF centres. J Cyst Fibros. 2010;9(2):104–109.
- Muhlebach MS, Thompson V, Popowitch E, et al. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomized controlled trial. Thorax. 2017;72(4):318–326.
- Dolce D, Neri S, Grisotto L, et al. Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: a randomized multicenter study. Plos One. 2019;14(3):e0213497.
- Vanderhelst E, De Wachter E, Willikens J, et al. Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of 11 patients. J Cyst Fibros. 2013;12(6):662–666.
- Dasenbrook EC, Merlo CA, Diener-West MD, et al. Persistent methicillin-resistant staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(8):814–821.
- Dezube R, Jennings MT, Rykiel M, et al. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros. 2019;18(3):357–363.
- Garske LA, Kidd TJ, Gan R, et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect. 2004;56(3):208–214.
- Vallières A, Rendall J, Moore J, et al. MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis. ERJ Open Res. 2016;2(1):00064–2015.